Safety issues about nevirapine administration in HIV-infected pregnant women.
Manfredi
Roberto
R
Calza
Leonardo
L
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D018791:CD4 Lymphocyte Count; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology*; D003257:Consumer Product Safety; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008099:Liver / Q000503:physiopathology; D019829:Nevirapine / Q000009:adverse effects* / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000276:immunology; D000637:Transaminases / Q000097:blood; D005723:gamma-Glutamyltransferase / Q000097:blood
D019380:Anti-HIV Agents; D019829:Nevirapine; D005723:gamma-Glutamyltransferase; D000637:Transaminases; D001663:Bilirubin